secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2022-11-04T23:59:59+00:00
Accession:  0001140361-22-040002
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Biosciences receives Nasdaq delisting notice for minimum bid price non-compliance
--------------------------------------------------------------------------------

- Received Nasdaq notice on Nov 2, 2022; stock closed below $1.00 for 30 consecutive trading days.
- Company has 180 calendar days, until May 1, 2023, to regain compliance with Minimum Bid Price Requirement.
- If bid price closes at or above $1.00 for 10 consecutive days before deadline, compliance achieved.
- If not cured, Nasdaq may grant a second 180-day grace period if Company meets other listing standards.
- Failure to cure could lead to delisting; Company may appeal to a Nasdaq hearings panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036122040002/0001140361-22-040002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036122040002/brhc10043734_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-040002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer